文献速递临床试验与 GCP

针对转运接受直接经皮冠状动脉介入治疗的ST段抬高型心肌梗死患者的院前脉冲糖皮质激素治疗:一项随机对照试验(PULSE-MI)

Pre-hospital pulse glucocorticoid therapy in patients with ST-segment elevation myocardial infarction transferred for primary percutaneous coronary intervention: a randomized controlled trial (PULSE-MI).
PubMed 文献 · Trials · 2023-12-15

PULSE-MI是一项随机、盲法、安慰剂对照的前瞻性II期临床试验,计划纳入378例STEMI患者,旨在评估院前给予250 mg甲泼尼龙静脉推注相比安慰剂能否减少直接PCI后3个月心脏磁共振测得的最终梗死面积。主要终点为晚期钆增强测定的最终梗死面积,次要终点包括关键CMR疗效参数、3个月临床终点、心脏生物标志物峰值及安全性。作者假设院前脉冲甲泼尼龙可减轻炎症并缩小梗死面积。

要点

  • 研究为随机、盲法、安慰剂对照II期试验,计划评估378例STEMI患者。
  • 干预为院前5分钟内静脉推注250 mg甲泼尼龙或匹配安慰剂,随机1:1分配。
  • 主要终点为STEMI后3个月心脏磁共振晚期钆增强测定的最终梗死面积。

核心结论

  • 作者假设院前给予脉冲剂量甲泼尼龙可减轻炎症,从而缩小接受直接PCI的STEMI患者的最终梗死面积。

研究设计与样本

  • 本研究为随机、盲法、安慰剂对照的前瞻性临床II期试验,纳入对象为在丹麦哥本哈根大学医院Rigshospitalet接受直接PCI的STEMI患者,计划评估378例患者的主要终点,随机1:1分配。

主要发现

  • 本文报告的是试验设计,未报告主要结局结果。
  • 计划在院前5分钟内静脉推注250 mg甲泼尼龙或匹配安慰剂。
  • 主要终点为STEMI后3个月心脏磁共振晚期钆增强测定的最终梗死面积。
  • 次要终点包括关键CMR疗效参数、3个月临床终点、心脏生物标志物峰值及安全性。

关键数值与推荐

  • 主要纳入标准包括年龄≥18岁、急性胸痛持续时间<12小时、心电图显示STEMI,并排除已知糖皮质激素过敏、既往冠状动脉旁路移植术、假定罪犯血管既往急性心肌梗死或既往躁狂/精神病发作史。
  • 主要终点为STEMI后3个月心脏磁共振晚期钆增强测定的最终梗死面积。

临床怎么用

  • 本文为试验设计报告,未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Inflammation in ST-segment elevation myocardial infarction (STEMI) is an important contributor to both acute myocardial ischemia and reperfusion injury after primary percutaneous coronary intervention (PCI). Methylprednisolone is a glucocorticoid with potent anti-inflammatory properties with an acute effect and is used as an effective and safe treatment of a wide range of acute diseases. The trial aims to investigate the cardioprotective effects of pulse-dose methylprednisolone administered in the pre-hospital setting in patients with STEMI transferred for primary PCI. METHODS: This trial is a randomized, blinded, placebo-controlled prospective clinical phase II trial. Inclusion will continue until 378 patients with STEMI have been evaluated for the primary endpoint. Patients will be randomized 1:1 to a bolus of 250 mg methylprednisolone intravenous or matching placebo over a period of 5 min in the pre-hospital setting. All patients with STEMI transferred for primary PCI at Rigshospitalet, Copenhagen University Hospital, Denmark, will be screened for eligibility. The main eligibility criteria are age ≥ 18 years, acute onset of chest pain with < 12 h duration, STEMI on electrocardiogram, no known allergy to glucocorticoids or no previous coronary artery bypass grafting, previous acute myocardial infarction in assumed culprit, or a history with previous maniac/psychotic episodes. Primary outcome is final infarct size measured by late gadolinium enhancement on cardiac magnetic resonance (CMR) 3 months after STEMI. Secondary outcomes comprise key CMR efficacy parameters, clinical endpoints at 3 months, the peak of cardiac biomarkers, and safety. DISCUSSION: We hypothesize that pulse-dose methylprednisolone administrated in the pre-hospital setting decreases inflammation and thus reduces final infarct size in patients with STEMI treated with primary PCI. TRIAL REGISTRATION: EU-CT number: 2022-500762-10-00; Submitted May 5, 2022. CLINICALTRIALS: gov Identifier: NCT05462730; Submitted July 7, 2022, first posted July 18, 2022.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Madsen JM, Obling LER, Rytoft L, et al. Pre-hospital pulse glucocorticoid therapy in patients with ST-segment elevation myocardial infarction transferred for primary percutaneous coronary intervention: a randomized controlled trial (PULSE-MI). Trials. 2023. PMID: 38102687. doi:10.1186/s13063-023-07830-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。